2Q EARNINGS: Dendreon, Amarin, Xoma slip on sales, clinical updates
This article was originally published in Scrip
Executive Summary
Shareholders were unimpressed with second quarter earnings reports from Dendreon, Amarin and Xoma, pushing two of the companies' stock prices down by double digits on 8 August.